AU2012327204B2 - Genetically modified T cell receptor mice - Google Patents

Genetically modified T cell receptor mice Download PDF

Info

Publication number
AU2012327204B2
AU2012327204B2 AU2012327204A AU2012327204A AU2012327204B2 AU 2012327204 B2 AU2012327204 B2 AU 2012327204B2 AU 2012327204 A AU2012327204 A AU 2012327204A AU 2012327204 A AU2012327204 A AU 2012327204A AU 2012327204 B2 AU2012327204 B2 AU 2012327204B2
Authority
AU
Australia
Prior art keywords
human
segments
animal
locus
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012327204A
Other languages
English (en)
Other versions
AU2012327204A1 (en
Inventor
Cagan Gurer
Lynn Macdonald
John Mcwhirter
Karolina A. Meagher
Andrew J. Murphy
Sean Stevens
Naxin Tu
Vera VORONINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2012327204A1 publication Critical patent/AU2012327204A1/en
Application granted granted Critical
Publication of AU2012327204B2 publication Critical patent/AU2012327204B2/en
Priority to AU2016202512A priority Critical patent/AU2016202512C1/en
Priority to AU2018204700A priority patent/AU2018204700C1/en
Priority to AU2021203192A priority patent/AU2021203192B2/en
Priority to AU2024204645A priority patent/AU2024204645A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2012327204A 2011-10-28 2012-10-26 Genetically modified T cell receptor mice Active AU2012327204B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2016202512A AU2016202512C1 (en) 2011-10-28 2016-04-20 Genetically modified t cell receptor mice
AU2018204700A AU2018204700C1 (en) 2011-10-28 2018-06-28 Genetically modified t cell receptor mice
AU2021203192A AU2021203192B2 (en) 2011-10-28 2021-05-18 Genetically modified t cell receptor mice
AU2024204645A AU2024204645A1 (en) 2011-10-28 2024-07-04 Genetically modified t cell receptor mice

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161552582P 2011-10-28 2011-10-28
US61/552,582 2011-10-28
US201261621198P 2012-04-06 2012-04-06
US61/621,198 2012-04-06
US201261700908P 2012-09-14 2012-09-14
US61/700,908 2012-09-14
PCT/US2012/062065 WO2013063361A1 (en) 2011-10-28 2012-10-26 Genetically modified t cell receptor mice

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202512A Division AU2016202512C1 (en) 2011-10-28 2016-04-20 Genetically modified t cell receptor mice

Publications (2)

Publication Number Publication Date
AU2012327204A1 AU2012327204A1 (en) 2013-05-23
AU2012327204B2 true AU2012327204B2 (en) 2016-01-21

Family

ID=47178340

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2012327204A Active AU2012327204B2 (en) 2011-10-28 2012-10-26 Genetically modified T cell receptor mice
AU2016202512A Active AU2016202512C1 (en) 2011-10-28 2016-04-20 Genetically modified t cell receptor mice
AU2018204700A Active AU2018204700C1 (en) 2011-10-28 2018-06-28 Genetically modified t cell receptor mice
AU2021203192A Active AU2021203192B2 (en) 2011-10-28 2021-05-18 Genetically modified t cell receptor mice
AU2024204645A Pending AU2024204645A1 (en) 2011-10-28 2024-07-04 Genetically modified t cell receptor mice

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2016202512A Active AU2016202512C1 (en) 2011-10-28 2016-04-20 Genetically modified t cell receptor mice
AU2018204700A Active AU2018204700C1 (en) 2011-10-28 2018-06-28 Genetically modified t cell receptor mice
AU2021203192A Active AU2021203192B2 (en) 2011-10-28 2021-05-18 Genetically modified t cell receptor mice
AU2024204645A Pending AU2024204645A1 (en) 2011-10-28 2024-07-04 Genetically modified t cell receptor mice

Country Status (25)

Country Link
US (4) US9113616B2 (cg-RX-API-DMAC7.html)
EP (3) EP3795587A1 (cg-RX-API-DMAC7.html)
JP (7) JP6254528B2 (cg-RX-API-DMAC7.html)
KR (5) KR102321909B1 (cg-RX-API-DMAC7.html)
CN (5) CN114891798B (cg-RX-API-DMAC7.html)
AU (5) AU2012327204B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014009203B1 (cg-RX-API-DMAC7.html)
CA (1) CA2853707A1 (cg-RX-API-DMAC7.html)
CY (2) CY1120945T1 (cg-RX-API-DMAC7.html)
DK (2) DK2771357T3 (cg-RX-API-DMAC7.html)
ES (2) ES2858978T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20181626T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053444T2 (cg-RX-API-DMAC7.html)
IL (4) IL274914B2 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03890A (cg-RX-API-DMAC7.html)
LT (2) LT3424947T (cg-RX-API-DMAC7.html)
MX (2) MX353134B (cg-RX-API-DMAC7.html)
PL (2) PL2771357T3 (cg-RX-API-DMAC7.html)
PT (2) PT2771357T (cg-RX-API-DMAC7.html)
RS (2) RS61455B1 (cg-RX-API-DMAC7.html)
RU (1) RU2661106C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201914043XA (cg-RX-API-DMAC7.html)
SI (2) SI3424947T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800553T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013063361A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014CN03890A (cg-RX-API-DMAC7.html) * 2011-10-28 2015-10-16 Regeneron Pharma
US20150073043A1 (en) * 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
PT2847335T (pt) 2012-04-25 2018-09-28 Regeneron Pharma Alvejamento mediado por nuclease com vetores de alvejamento grandes
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
HUE040575T2 (hu) 2013-04-16 2019-03-28 Regeneron Pharma A patkány genom célzott módosítása
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
LT3152312T (lt) * 2014-06-06 2020-04-27 Regeneron Pharmaceuticals, Inc. Tikslinio lokuso modifikavimo būdai ir kompozicijos
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
EP3461885B1 (en) 2014-06-26 2021-10-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
HUE044907T2 (hu) 2014-11-21 2019-11-28 Regeneron Pharma Módszerek és készítmények célzott genetikai módosításhoz, párosított mutató RNS-ek használatával
RS63410B1 (sr) * 2014-11-24 2022-08-31 Regeneron Pharma Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
NZ732895A (en) 2014-12-19 2022-05-27 Regeneron Pharma Methods and compositions for targeted genetic modification through single-step multiple targeting
DK3280257T3 (da) * 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
EP3291679B1 (en) 2015-05-06 2021-12-15 SNIPR Technologies Limited Altering microbial populations & modifying microbiota
LT3376857T (lt) * 2015-11-20 2021-06-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
AU2017248259A1 (en) * 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
CR20180531A (es) 2016-04-08 2019-06-13 Immunocore Ltd Receptores de células t
EP3462853B1 (en) * 2016-06-03 2023-03-01 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3638262A4 (en) * 2017-06-16 2021-03-24 Mayo Foundation for Medical Education and Research MATERIALS AND METHODS FOR INCREASING IMMUNE REACTION
CN111954679A (zh) 2017-10-03 2020-11-17 朱诺治疗学股份有限公司 Hpv特异性结合分子
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
MX2020010459A (es) * 2018-04-05 2021-01-20 Juno Therapeutics Inc Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
SG11202101789SA (en) * 2018-07-26 2021-03-30 Univ Kyoto Method for generating cells into which an exogenous antigen receptor is introduced
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CA3154287A1 (en) * 2019-09-12 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CA3177181A1 (en) * 2020-03-27 2021-09-30 2Seventy Bio, Inc. T cell receptors
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
US20240114883A1 (en) * 2022-08-12 2024-04-11 Ingenious Targeting Laboratories Genetically modified non-human having humanized gamma and delta TCR variable genes
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
KR20250077529A (ko) * 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
TW202520975A (zh) 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
GB2640828A (en) 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs
GB202405657D0 (en) 2024-04-22 2024-06-05 T Therapeutics Ltd T cell receptor identification and provision

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059263A2 (en) * 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
WO2011004192A1 (en) * 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
US6320306B1 (en) * 1996-08-05 2001-11-20 Samsung Display Devices Co., Ltd. Shadow mask with porous insulating layer and heavy metal layer
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
CA2457652C (en) 2001-08-31 2012-08-07 Avidex Limited Soluble t cell receptor
US20050177884A1 (en) 2001-11-15 2005-08-11 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal
WO2003068819A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
DE60106469T2 (de) 2001-12-22 2005-10-13 4-Antbody AG Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
US20060156419A1 (en) 2002-10-30 2006-07-13 The Wistar Institute Of Anatomy And Biology Mouse model for autoimmune disorders
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008051854A2 (en) 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
JP2008159109A (ja) 2006-12-21 2008-07-10 Matsushita Electric Ind Co Ltd データ転送装置
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
WO2010107400A1 (en) * 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
CN103348012B (zh) 2010-11-27 2016-06-08 朱坚 一种人源化的转基因动物
IN2014CN03890A (cg-RX-API-DMAC7.html) * 2011-10-28 2015-10-16 Regeneron Pharma
DK3280257T3 (da) 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059263A2 (en) * 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
WO2011004192A1 (en) * 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Also Published As

Publication number Publication date
JP2023024744A (ja) 2023-02-16
CN107858333B (zh) 2022-05-27
SMT201800553T1 (it) 2018-11-09
BR112014009203A2 (pt) 2020-10-27
US20130109053A1 (en) 2013-05-02
IL305550B2 (en) 2025-02-01
SG10201914043XA (en) 2020-03-30
RU2014121160A (ru) 2015-12-10
PL3424947T3 (pl) 2021-06-14
EP2771357B1 (en) 2018-07-18
AU2016202512C1 (en) 2018-10-11
JP2020146045A (ja) 2020-09-17
LT3424947T (lt) 2021-03-10
AU2024204645A1 (en) 2024-08-01
IL305550B1 (en) 2024-10-01
HRP20210256T1 (hr) 2021-04-02
JP7656580B2 (ja) 2025-04-03
HUE053444T2 (hu) 2021-06-28
ES2858978T3 (es) 2021-09-30
HRP20181626T1 (hr) 2018-12-14
IL305550A (en) 2023-10-01
CN114891797A (zh) 2022-08-12
PL2771357T3 (pl) 2018-12-31
US20220386575A1 (en) 2022-12-08
JP6706311B2 (ja) 2020-06-03
HK1198171A1 (en) 2015-03-13
NZ623147A (en) 2016-03-31
IL274914B1 (en) 2023-10-01
AU2016202512B2 (en) 2018-03-29
IL232098B (en) 2020-06-30
JP2024019646A (ja) 2024-02-09
CN104011071B (zh) 2017-11-07
PT3424947T (pt) 2021-03-01
IN2014CN03890A (cg-RX-API-DMAC7.html) 2015-10-16
ES2691475T3 (es) 2018-11-27
IL315445A (en) 2024-11-01
WO2013063361A1 (en) 2013-05-02
CN107858332A (zh) 2018-03-30
RU2661106C2 (ru) 2018-07-11
JP2022093637A (ja) 2022-06-23
SI2771357T1 (sl) 2018-11-30
AU2021203192B2 (en) 2024-04-11
IL274914A (en) 2020-07-30
LT2771357T (lt) 2018-10-25
EP2771357A1 (en) 2014-09-03
SMT202100243T1 (it) 2021-05-07
KR20220066197A (ko) 2022-05-23
DK3424947T3 (da) 2021-02-22
DK2771357T3 (en) 2018-10-29
US9113616B2 (en) 2015-08-25
AU2021203192A1 (en) 2021-06-10
EP3424947B1 (en) 2020-11-25
SI3424947T1 (sl) 2021-04-30
US11528895B2 (en) 2022-12-20
AU2012327204A1 (en) 2013-05-23
US20160021856A1 (en) 2016-01-28
CN104011071A (zh) 2014-08-27
KR20200102001A (ko) 2020-08-28
AU2018204700C1 (en) 2021-10-14
CA2853707A1 (en) 2013-05-02
JP2019033770A (ja) 2019-03-07
CY1120945T1 (el) 2019-12-11
US20210051930A1 (en) 2021-02-25
KR20140077219A (ko) 2014-06-23
JP6532924B2 (ja) 2019-06-19
EP3424947A1 (en) 2019-01-09
CN114891798A (zh) 2022-08-12
IL232098A0 (en) 2014-05-28
RS57893B1 (sr) 2019-01-31
AU2018204700A1 (en) 2018-07-19
JP6254528B2 (ja) 2017-12-27
JP2018007696A (ja) 2018-01-18
IL274914B2 (en) 2024-02-01
KR102148387B1 (ko) 2020-08-26
BR112014009203B1 (pt) 2023-02-28
JP7305840B2 (ja) 2023-07-10
KR102542272B1 (ko) 2023-06-13
KR20210133325A (ko) 2021-11-05
KR102397961B1 (ko) 2022-05-13
RS61455B1 (sr) 2021-03-31
SG11201401030WA (en) 2014-04-28
AU2016202512A1 (en) 2016-05-12
CN107858333A (zh) 2018-03-30
CN114891798B (zh) 2025-12-02
PT2771357T (pt) 2018-11-09
MX353134B (es) 2017-12-20
AU2018204700B2 (en) 2021-04-01
JP2014532413A (ja) 2014-12-08
KR102321909B1 (ko) 2021-11-05
CY1123831T1 (el) 2022-05-27
KR101964776B1 (ko) 2019-04-04
EP3795587A1 (en) 2021-03-24
MX379517B (es) 2025-03-10
MX2014004894A (es) 2014-09-12
KR20190037354A (ko) 2019-04-05

Similar Documents

Publication Publication Date Title
AU2021203192B2 (en) Genetically modified t cell receptor mice
HK40049273A (en) Genetically modified t cell receptor mice
HK40002846B (en) Genetically modified t cell receptor mice
HK40002846A (en) Genetically modified t cell receptor mice
HK1198171B (en) Genetically modified t cell receptor mice
NZ623147B2 (en) Genetically modified t cell receptor mice

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MACDONALD, LYNN; MURPHY, ANDREW J.; MCWHIRTER, JOHN; TU, NAXIN; VORONINA, VERA; GURER, CAGAN; HOSIAWA, KAROLINA AND STEVENS, SEAN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MACDONALD, LYNN; MURPHY, ANDREW J.; MCWHIRTER, JOHN; TU, NAXIN; VORONINA, VERA; GURER, CAGAN; MEAGHER, KAROLINA A. AND STEVENS, SEAN

FGA Letters patent sealed or granted (standard patent)